Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
Authors
Richard S. Finn
Department of Medicine, Hematology/Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA;
Richard S. Finn , Shukui Qin , Masatoshi Kudo , Tim Meyer , Frederic Boisserie , Songzi Li , Yaxi Chen , Gisoo Barnes , Ramil Abdrashitov , Andrew X. Zhu , Arndt Vogel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT03412773
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 495)
DOI
10.1200/JCO.2023.41.4_suppl.495
Abstract #
495
Poster Bd #
A5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
First Author: Richard S. Finn
Poster
2023 ASCO Annual Meeting
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
First Author: Arndt Vogel
Poster
2023 ASCO Annual Meeting
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
First Author: Masatoshi Kudo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab + rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC).
First Author: Stephen Lam Chan